Pay vs Performance Disclosure - USD ($)

12 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2022

Jun. 30, 2021

Pay vs Performance Disclosure

Pay vs Performance Disclosure, Table

Fiscal Year	Summary Compensation Table Total for PEO(1)			Compensation Actually Paid to PEO(2)			Average Summary Compensation Table Total for non-PEO NEOs(3)			Average Compensation Actually Paid to non-PEO NEOs(4)			Value of Initial Fixed $100 Investment Based On:						Net Income ($M)			Adjusted Net Sales ($M)(6)
													RMD Total Shareholder Return			Dow Jones US Med. Equipment Total Shareholder Return(5)
2024		$	14,120,829		$	10,329,790		$	3,129,017		$	2,578,989		$	99.70		$	131.90		$	1,021.0		$	4,720.2
2023		$	13,868,641		$	16,867,038		$	4,147,542		$	4,909,275		$	113.80		$	129.79		$	897.6		$	4,163.2
2022		$	11,659,215		$	4,374,620		$	3,625,326		$	-55,486		$	109.18		$	114.04		$	779.4		$	3,616.1
2021		$	10,389,326		$	32,799,199		$	4,165,235		$	12,203,786		$	128.40		$	135.10		$	474.5		$	3,174.3

Company Selected Measure Name

Adjusted Net Sales

Named Executive Officers, Footnote

ResMed had one Principal Executive Officer or “PEO”, Mr. Michael Farrell, during fiscal years 2024, 2023, 2022, and 2021.Non-PEO NEOs included for the fiscal years 2024, 2023, 2022 and 2021 are reflected in the table below:

Fiscal Year	Non-PEO NEOs
2024	Bobby Ghoshal, Justin Leong, Michael Rider, Brett Sandercock
2023	Lucile Blaise, Rob Douglas, Bobby Ghoshal, Brett Sandercock
2022	Rob Douglas, Bobby Ghoshal, Jim Hollingshead, David Pendarvis, Brett Sandercock
2021	Rob Douglas, Jim Hollingshead, Brett Sandercock, Raj Sodhi

Peer Group Issuers, Footnote

The Dow Jones U.S. Medical Equipment index is one of the two index peer groups disclosed in our 10-K and we selected this index as our peer group for purposes of this disclosure, which is comprised of 61 companies from the Dow Jones U.S. Broad Stock Market Index that are classified in the DJICS Medical Equipment subsection. The Company’s relative TSR PSUs did not use this relative TSR as a financial performance measure. See the CD&A section titled “Long Term Incentives” in this Proxy Statement for additional information.

PEO Total Compensation Amount

$ 14,120,829

$ 13,868,641

$ 11,659,215

$ 10,389,326

PEO Actually Paid Compensation Amount

$ 10,329,790

16,867,038

4,374,620

32,799,199

Adjustment To PEO Compensation, Footnote

SEC rules require certain adjustments be made to the “Total” column as reported in the Summary Compensation Table to determine “Compensation Actually Paid” as reported in the Pay versus Performance Table (“PVP Table”). “Compensation Actually Paid” does not necessarily represent cash and/or equity value transferred to the applicable NEO without restriction, but rather is a value calculated under applicable SEC rules. The equity values are calculated in accordance with ASC Topic 718, with dividends being reflected in the fair value of the award. Valuation assumptions used to calculate fair values used a consistent process as done on the date of grant and were not materially different from those disclosed at the time of grant. The closing stock price of our common stock on June 30, 2020, June 30, 2021, June 30, 2022, June 30, 2023 and June 28, 2024, was $192.00, $246.52, $209.63, $218.50 and $191.42, respectively. The following tables detail these adjustments for the PEO:

PEO
Prior FYE	6/30/2020			6/30/2021			6/30/2022			6/30/2023
Current FYE	6/30/2021			6/30/2022			6/30/2023			6/30/2024
Fiscal Year	2021			2022			2023			2024
Summary Compensation Table Total		$	10,389,326		$	11,659,215		$	13,868,641		$	14,120,829
- Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year		$	(7,700,011)		$	(9,000,005)		$	(10,999,975)		$	(11,200,082)
+ Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year		$	9,967,171		$	6,170,624		$	10,216,009		$	15,633,403
+ Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years		$	15,351,855		$	(5,637,001)		$	(1,315,735)		$	(6,504,731)
+ Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year		$	—		$	—		$	—		$	—
+ Change in Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year		$	4,790,858		$	1,181,787		$	5,098,098		$	(1,719,629)
- Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year		$	—		$	—		$	—		$	—
Total Adjustments		$	22,409,873		$	(7,284,595)		$	2,998,397		$	(3,791,039)
Compensation Actually Paid		$	32,799,199		$	4,374,620		$	16,867,038		$	10,329,790

Non-PEO NEO Average Total Compensation Amount

$ 3,129,017

4,147,542

3,625,326

4,165,235

Non-PEO NEO Average Compensation Actually Paid Amount

$ 2,578,989

4,909,275

(55,486)

12,203,786

Adjustment to Non-PEO NEO Compensation Footnote

As discussed in footnote 2, SEC rules require certain adjustments to be made to determine “compensation actually paid” as reported in the Pay versus Performance table above. The following table details these adjustments to the Average Summary Compensation Table Total for Non-PEO NEOs.

Average of Non-PEO NEOs
Prior FYE	6/30/2020			6/30/2021			6/30/2022			6/30/2023
Current FYE	6/30/2021			6/30/2022			6/30/2023			6/30/2024
Fiscal Year	2021			2022			2023			2024
Summary Compensation Table Total		$	4,165,235		$	3,625,326		$	4,147,542		$	3,129,017
- Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year		$	(2,775,010)		$	(2,500,046)		$	(2,821,097)		$	(2,074,926)
+ Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year		$	3,708,490		$	1,328,777		$	2,643,811		$	2,725,662
+ Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years		$	5,495,623		$	(1,432,485)		$	(346,310)		$	(911,343)
+ Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year		$	—		$	—		$	—		$	—
+ Change in Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year		$	1,609,448		$	390,289		$	1,285,329		$	(289,421)
- Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year		$	—		$	(1,467,347)		$	—		$	—
Total Adjustments		$	8,038,551		$	(3,680,812)		$	761,733		$	(550,028)
Compensation Actually Paid		$	12,203,786		$	(55,486)		$	4,909,275		$	2,578,989

Compensation Actually Paid vs. Total Shareholder Return

Compensation Actually Paid vs. ResMed & Peer TSR

n PEO CAP ($M) n Average Non-PEO NEO CAP ($M)   RMD TSR   Dow Jones U.S. Medical Equipment Index TSR

Compensation Actually Paid vs. Net Income

Compensation Actually Paid vs. RMD Net Income

n PEO CAP ($M) n Average Non-PEO NEO CAP ($M)   Net Income($M)

Compensation Actually Paid vs. Company Selected Measure

Compensation Actually Paid vs. Adjusted Net Sales

n PEO CAP ($M) n Average Non-PEO NEO CAP ($M)   Adjusted Net Sales ($M)

Total Shareholder Return Vs Peer Group

Compensation Actually Paid vs. ResMed & Peer TSR

n PEO CAP ($M) n Average Non-PEO NEO CAP ($M)   RMD TSR   Dow Jones U.S. Medical Equipment Index TSR

Tabular List, Table

Financial Performance Measures

Adjusted Net Sales

Net Operating Profit

Total Shareholder Return (absolute TSR)

Relative Total Shareholder Return (relative TSR)

Total Shareholder Return Amount

$ 99.70

113.80

109.18

128.40

Peer Group Total Shareholder Return Amount

131.90

129.79

114.04

135.10

Net Income (Loss)

$ 1,021,000,000

$ 897,600,000

$ 779,400,000

$ 474,500,000

Company Selected Measure Amount

4,720,200,000

4,163,200,000

3,616,100,000

3,174,300,000

PEO Name

Mr. Michael Farrell

Mr. Michael Farrell

Mr. Michael Farrell

Mr. Michael Farrell

Additional 402(v) Disclosure

Analysis of the Information Presented in the Pay versus Performance Table

In this section, we provide a graphic analysis showing, for the past four years, the relationship between our PEO’s and the Average of the Non-PEO NEOs’ “Compensation Actually Paid” and (i) the Company’s Adjusted Net Sales, (ii) the Company’s Net Income and (iii) the Company’s TSR, and additionally, the TSR of the Dow Jones U.S. Medical Equipment Index, one of the disclosed peer groups from our 10-K filing. As described in more detail in the CD&A, our executive compensation program reflects a pay-for-performance philosophy that emphasizes long-term equity awards intended to align our executives’ interests with stockholders’ long-term interests. Thus, the value of these awards and, therefore, a large portion of the compensation actually paid to our NEOs is inherently correlated to the Company’s stock price over time. Please refer to the section entitled CD&A above for more information about our executive compensation program.

Measure:: 1

Pay vs Performance Disclosure

Name

Adjusted Net Sales

Non-GAAP Measure Description

Adjusted Net Sales represents the most important financial performance measure (that is not otherwise required to be disclosed in the table) used by the Company to link compensation actually paid to our NEOs, including our Chief Executive Officer, for the most recently completed fiscal year to the Company’s performance. Up to 50% of cash incentive opportunity for our NEOs is based on our Adjusted Net Sales performance. Adjusted Net Sales is a non-GAAP measure and is calculated as net sales on a GAAP basis excluding the impact of revenue from acquisitions completed after the establishment of the internal financial plan, as applicable, and foreign currency fluctuations. For a reconciliation of Adjusted Net Sales to the most directly comparable GAAP financial measure and insight into how Adjusted Net Sales is considered by management, please see Page 59 under “Elements of Compensation - Annual Cash Incentive Plan - Incentive Plan Adjustments.”

Measure:: 2

Pay vs Performance Disclosure

Name

Net Operating Profit

Measure:: 3

Pay vs Performance Disclosure

Name

Total Shareholder Return (absolute TSR)

Measure:: 4

Pay vs Performance Disclosure

Name

Relative Total Shareholder Return (relative TSR)

PEO

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

$ (3,791,039)

$ 2,998,397

$ (7,284,595)

$ 22,409,873

PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(11,200,082)

(10,999,975)

(9,000,005)

(7,700,011)

PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

15,633,403

10,216,009

6,170,624

9,967,171

PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(6,504,731)

(1,315,735)

(5,637,001)

15,351,855

PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

0

0

0

0

PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(1,719,629)

5,098,098

1,181,787

4,790,858

PEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

0

0

0

0

Non-PEO NEO

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(550,028)

761,733

(3,680,812)

8,038,551

Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(2,074,926)

(2,821,097)

(2,500,046)

(2,775,010)

Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

2,725,662

2,643,811

1,328,777

3,708,490

Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(911,343)

(346,310)

(1,432,485)

5,495,623

Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

0

0

0

0

Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(289,421)

1,285,329

390,289

1,609,448

Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

$ 0

$ 0

$ (1,467,347)

$ 0